FDA guidances provide clarity on compounding exceptions

FDA released two draft guidance documents that provide clarity on the agency's thinking on sections 503A and 503B of the Food, Drug & Cosmetics Act, which restrict compounding of drugs that are essentially a copy of a commercially available

Read the full 390 word article

How to gain access

Continue reading with a
two-week free trial.